Eui Jung Moon1, Kristoffer Petersson1,2, Monica M Olcina1. 1. MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. 2. Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Abstract
PURPOSE: Hypoxia (low oxygen) is a common feature of solid tumors that has been intensely studied for more than six decades. Here we review the importance of hypoxia to radiotherapy with a particular focus on the contribution of hypoxia to immune responses, metastatic potential and FLASH radiotherapy, active areas of research by leading women in the field. CONCLUSION: Although hypoxia-driven metastasis and immunosuppression can negatively impact clinical outcome, understanding these processes can also provide tumor-specific vulnerabilities that may be therapeutically exploited. The different oxygen tensions present in tumors and normal tissues may underpin the beneficial FLASH sparing effect seen in normal tissue and represents a perfect example of advances in the field that can leverage tumor hypoxia to improve future radiotherapy treatments.
PURPOSE: Hypoxia (low oxygen) is a common feature of solid tumors that has been intensely studied for more than six decades. Here we review the importance of hypoxia to radiotherapy with a particular focus on the contribution of hypoxia to immune responses, metastatic potential and FLASH radiotherapy, active areas of research by leading women in the field. CONCLUSION: Although hypoxia-driven metastasis and immunosuppression can negatively impact clinical outcome, understanding these processes can also provide tumor-specific vulnerabilities that may be therapeutically exploited. The different oxygen tensions present in tumors and normal tissues may underpin the beneficial FLASH sparing effect seen in normal tissue and represents a perfect example of advances in the field that can leverage tumor hypoxia to improve future radiotherapy treatments.
Entities:
Keywords:
FLASH; cancer; immune system; metastasis; tumor microenvironment; ultra-high dose rate; women in research
Authors: Verna McErlane; Anita Yakkundi; Helen O McCarthy; Ciara M Hughes; Laurence H Patterson; David G Hirst; Tracy Robson; Stephanie R McKeown Journal: J Gene Med Date: 2005-07 Impact factor: 4.565
Authors: Tiril Hillestad; Tord Hompland; Christina S Fjeldbo; Vilde E Skingen; Unn Beate Salberg; Eva-Katrine Aarnes; Anja Nilsen; Kjersti V Lund; Tina S Evensen; Gunnar B Kristensen; Trond Stokke; Heidi Lyng Journal: Cancer Res Date: 2020-06-30 Impact factor: 12.701
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: Monica M Olcina; Nikolas G Balanis; Ryan K Kim; B Arman Aksoy; Julia Kodysh; Michael J Thompson; Jeff Hammerbacher; Thomas G Graeber; Amato J Giaccia Journal: Cell Rep Date: 2018-12-26 Impact factor: 9.423
Authors: Gabriel Adrian; Elise Konradsson; Sarah Beyer; Anders Wittrup; Karl T Butterworth; Stephen J McMahon; Mihaela Ghita; Kristoffer Petersson; Crister Ceberg Journal: Front Oncol Date: 2021-07-29 Impact factor: 6.244
Authors: Manal Mehibel; Yu Xu; Caiyun G Li; Eui Jung Moon; Kaushik N Thakkar; Anh N Diep; Ryan K Kim; Joshua D Bloomstein; Yiren Xiao; Julien Bacal; Joshua C Saldivar; Quynh-Thu Le; Karlene A Cimprich; Erinn B Rankin; Amato J Giaccia Journal: J Clin Invest Date: 2021-06-01 Impact factor: 19.456